THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES

F. Aiuti, M. Fiorilli, I. Quinti, R. Seminara, L. Businco, E. Galli, P. Rossi, G. Goldstein

Research output: Contribution to journalArticle

Abstract

26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.

Original languageEnglish
Pages (from-to)551-555
Number of pages5
JournalLancet
Volume321
Issue number8324
DOIs
Publication statusPublished - Mar 12 1983

Fingerprint

Thymopentin
Severe Combined Immunodeficiency
T-Lymphocytes
Job Syndrome
DiGeorge Syndrome
Ataxia Telangiectasia
B-Lymphocytes
X-Linked Combined Immunodeficiency Diseases
Common Variable Immunodeficiency
Therapeutics
Immunologic Tests

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Aiuti, F., Fiorilli, M., Quinti, I., Seminara, R., Businco, L., Galli, E., ... Goldstein, G. (1983). THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES. Lancet, 321(8324), 551-555. https://doi.org/10.1016/S0140-6736(83)92810-6

THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES. / Aiuti, F.; Fiorilli, M.; Quinti, I.; Seminara, R.; Businco, L.; Galli, E.; Rossi, P.; Goldstein, G.

In: Lancet, Vol. 321, No. 8324, 12.03.1983, p. 551-555.

Research output: Contribution to journalArticle

Aiuti, F, Fiorilli, M, Quinti, I, Seminara, R, Businco, L, Galli, E, Rossi, P & Goldstein, G 1983, 'THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES', Lancet, vol. 321, no. 8324, pp. 551-555. https://doi.org/10.1016/S0140-6736(83)92810-6
Aiuti F, Fiorilli M, Quinti I, Seminara R, Businco L, Galli E et al. THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES. Lancet. 1983 Mar 12;321(8324):551-555. https://doi.org/10.1016/S0140-6736(83)92810-6
Aiuti, F. ; Fiorilli, M. ; Quinti, I. ; Seminara, R. ; Businco, L. ; Galli, E. ; Rossi, P. ; Goldstein, G. / THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES. In: Lancet. 1983 ; Vol. 321, No. 8324. pp. 551-555.
@article{909e94ed10514104882f5cd99cb6bb17,
title = "THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES",
abstract = "26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.",
author = "F. Aiuti and M. Fiorilli and I. Quinti and R. Seminara and L. Businco and E. Galli and P. Rossi and G. Goldstein",
year = "1983",
month = "3",
day = "12",
doi = "10.1016/S0140-6736(83)92810-6",
language = "English",
volume = "321",
pages = "551--555",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Lancet Publishing Group",
number = "8324",

}

TY - JOUR

T1 - THYMOPOIETIN PENTAPEPTIDE TREATMENT OF PRIMARY IMMUNODEFICIENCIES

AU - Aiuti, F.

AU - Fiorilli, M.

AU - Quinti, I.

AU - Seminara, R.

AU - Businco, L.

AU - Galli, E.

AU - Rossi, P.

AU - Goldstein, G.

PY - 1983/3/12

Y1 - 1983/3/12

N2 - 26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.

AB - 26 patients with primary immunodeficiencies (3 infants with severe combined immunodeficiency [SCID] 3 with DiGeorge syndrome, 6 with T-cell defect or SCID with B cells, 4 with common variable hypogammaglobulinaemia and associated T-cell defect, 5 with ataxia-telangiectasia, and 5 with hyper-IgE syndrome) were treated with thymopoietin pentapeptide (TP-5) at a dose of 0·5 mg/kg daily for 2 weeks and then 3 times a week at 0·5 mg/kg for 10 weeks. 3 patients with DiGeorge syndrome and 3 with primary T-cell defect demonstrated pronounced clinical and immunological improvement during treatment. None of the patients with SCID and 3 of 6 patients with SCID with B cells or primary T-cell defect showed any clinical or immunological changes during therapy. In 5 patients with ataxia-telangiectasia clinical manifestations and immunological tests were unchanged by TP-5. Abnormality of T cells in cases of hyper-IgE syndrome was not corrected by TP-5 treatment.

UR - http://www.scopus.com/inward/record.url?scp=0020699783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020699783&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(83)92810-6

DO - 10.1016/S0140-6736(83)92810-6

M3 - Article

C2 - 6131256

AN - SCOPUS:0020699783

VL - 321

SP - 551

EP - 555

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8324

ER -